CTCs with E–M plasticity are able to secrete TGFβ, which serves as a potent inhibitor of NK cytotoxicity against tumor cells by downregulating activating receptor NKG2D expression on NK cells [286]. The gene discussed is TGFB1; the disease is neoplasm.